Current Hypertension Reports

, Volume 6, Issue 4, pp 314–320 | Cite as

Lead-induced hypertension: Role of oxidative stress

  • Nosratola D. Vaziri
  • Domenic A. Sica


Chronic, low-level lead exposure causes hypertension in both animals and humans. The pathogenesis of leadinduced hypertension is multifactorial, including such diverse mechanisms as: inactivation of endogenous nitric oxide and downregulation of soluble guanylate cyclase by reactive oxygen species (ROS), leading to a functional deficiency in nitric oxide; heightened sympathetic activity and plasma norepinephrine together with depressed vascular and elevated renal β-adrenergic receptor density; elevated plasma angiotensin-converting enzyme (ACE) activity, plasma renin activity (PRA), angiotensin II (Ang-II), and aldosterone levels; increased kininase I and kininase II activities; lead-induced inhibition of vascular smooth muscle Na+-K+ ATPase, leading to a rise in cellular Na+ and, hence, Ca2+; and a possible rise in endothelin and thromboxane generation. In this article, we present an overview of the epidemiology and proposed underlying mechanisms of lead-induced hypertension.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sharp DS, Osterloh J, Becker CE, et al.: Blood pressure and blood lead concentration in bus drivers. Environ Health Perspect 1988, 78:131–137.PubMedCrossRefGoogle Scholar
  2. 2.
    Harlan WR: The relationship of blood lead levels to blood pressure in the U.S. population. Environ Health Perspect 1988, 78:9–13.PubMedCrossRefGoogle Scholar
  3. 3.
    Khalil-Manesh F, Gonick HC, Weiler EW, et al.: Lead induced hypertension: possible role of endothelial factors. Am J Hypertens 1993, 6:723–729.PubMedGoogle Scholar
  4. 4.
    Vaziri ND, Ding Y, Ni Z, Gonick HC: Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 1997, 52:1042–1046.PubMedCrossRefGoogle Scholar
  5. 5.
    Gonick HC, Ding Y, Bondy SC, et al.: Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species. Hypertension 1997, 30:1487–1492.PubMedGoogle Scholar
  6. 6.
    Pirkle JL, Kaufmann RB, Brody DJ, et al.: Exposure of the U.S. population to lead, 1991–1994. Environ Health Perspect 1998, 106:745–750.PubMedCrossRefGoogle Scholar
  7. 7.
    Lustberg M, Silbergold E: Blood lead levels and mortality. Arch Intern Med 2002, 162:2443–2449.PubMedCrossRefGoogle Scholar
  8. 8.
    Vupputuri S, Muntner P, Bazzano LA, et al.: Blood lead level is associated with elevated blood pressure in blacks. Hypertension 2003, 41:463–468.PubMedCrossRefGoogle Scholar
  9. 9.
    Hond DE, Nawrot T, Staessen JA: The relationship between blood pressure and blood lead in NHANES III. J Hum Hypertens 2002, 16:563–568. Relevant broad-based evaluation of the relationship between blood lead levels and blood pressure.CrossRefGoogle Scholar
  10. 10.
    Webb RC, Winquist RJ, Victery W, Vander AJ: In vivo and in vitro effects of lead on vascular reactivity in rats. Am J Physiol 1981, 241:H211-H216.PubMedGoogle Scholar
  11. 11.
    Chang HR, Chen SS, Chen TJ, et al.: Lymphocyte beta-2 adrenergic receptors and plasma catecholamine levels in lead-exposed workers. Toxicol Appl Pharmacol 1996, 139:1–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Castellino N, Castellino P, Sannolo N: Inorganic Lead Exposure: Metabolism and Intoxication. Boca Raton: Lewis Publisher, 1995.Google Scholar
  13. 13.
    Sokas RK, Simmens S, Sophar K, et al.: Lead levels in Maryland construction workers. Am J Ind Med 1997, 31:188–194.PubMedCrossRefGoogle Scholar
  14. 14.
    Menditto A, Morisi G, Spagnolo A, Mencotti A: Association of blood lead to blood pressure in men aged 55 to 75 years: effects of selected social and biochemical cofounders. Environ Health Perspect 1994, 102:107–111.PubMedGoogle Scholar
  15. 15.
    Hu H, Aro A, Payton M, et al.: The relationship of bone and blood lead to hypertension: the normative aging study. JAMA 1996, 275:1171–1176.PubMedCrossRefGoogle Scholar
  16. 16.
    Shen X, Rosen JF, Guo D, Wu S: Childhood lead poisoning in China. Sci Total Environ 1996, 181:101–109.PubMedCrossRefGoogle Scholar
  17. 17.
    Postoli P, Maranelli G, Micciolo R: Is hypertension a confounding factor in the assessment of blood lead reference values? Sci Total Environ 1992, 120:127–134.CrossRefGoogle Scholar
  18. 18.
    Moller L, Kristensen TS: Blood lead as a cardiovascular risk factor. Am J Epidemiol 1992, 136:1091–1100.PubMedGoogle Scholar
  19. 19.
    Pirkle JL, Schwartz J, Landis JR, Harlan WR: The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol 1985, 121:246–258.PubMedGoogle Scholar
  20. 20.
    Rothenberg SJ, Kondrashov V, Manalo M, et al.: Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. Am J Epidemiol 2002, 156:1079–1087.PubMedCrossRefGoogle Scholar
  21. 21.
    Glenn BS, Stewart WF, Links JM, et al.: The longitudinal association of lead with blood pressure. Epidemiology 2003, 14:30–36.PubMedCrossRefGoogle Scholar
  22. 22.
    Nash D, Magder L, Lustberg L, et al.: Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. J Am Med Assoc 2003, 289:1523–1532. Careful delineation of blood lead and blood pressure associations in relation to menopausal status.CrossRefGoogle Scholar
  23. 23.
    Staessen JA, Roels H, Lauwerys RR, Amery A: Low-level lead exposure and blood pressure. J Hum Hypertens 1995, 9:303–328.PubMedGoogle Scholar
  24. 24.
    Hu H: Poorly controlled hypertension in a painter with chronic lead toxicity. Environ Health Perspect 2001, 109:95–99.PubMedCrossRefGoogle Scholar
  25. 25.
    Nilsson U, Attewell R, Christoffersson JO, et al.: Kinetics of lead in the bone and blood after the end of occupational exposure. Pharmacol Toxicol 1991, 68:477–484.PubMedGoogle Scholar
  26. 26.
    Rothenberg SJ, Kondrashov V, Manalo M, et al.: Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. Am J Epidemiol 2002, 156:1079–1087.PubMedCrossRefGoogle Scholar
  27. 27.
    Webber CE, Chettle DR, Bowins RJ, et al.: Hormone replacement therapy may reduce the return of endogenous lead from bone to the circulation. Environ Health Perspect 1995, 103:1150–1153.PubMedCrossRefGoogle Scholar
  28. 28.
    Garrido Latorre F, Hernandez-Avila M, Tamayo Orozco J, et al.: Relationship of blood and bone lead to menopause and bone mineral density among middle-age women in Mexico City. Environ Health Perspect 2003, 111:631–636.Google Scholar
  29. 29.
    Fleet JC: Bone lead as a risk factor for hypertension in men. Nutr Rev 1996, 54:180–182.PubMedCrossRefGoogle Scholar
  30. 30.
    Batuman V: Lead nephropathy, gout and hypertension. Am J Med Sci 1993, 305:241–247.PubMedCrossRefGoogle Scholar
  31. 31.
    Houston DK, Johnson MA: Lead as a risk factor for hypertension in women. Nutr Rev 1999, 57:227–279.Google Scholar
  32. 32.
    Cheng Y, Schwartz J, Sparrow D, et al.: Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the normotensive aging study. Am J Epidemiol 2001, 153:164–171.PubMedCrossRefGoogle Scholar
  33. 33.
    Muntner P, He J, Vupputuri S, et al.: Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 2003, 63:1044–1050.PubMedCrossRefGoogle Scholar
  34. 34.
    Vaziri ND, Ding Y, Ni Z: Nitric oxide synthase expression in the course of lead-induced hypertension. Hypertension 1999, 34:558–562.PubMedGoogle Scholar
  35. 35.
    Vaziri ND, Liang K, Ding Y: Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 1999, 56:1492–1498.PubMedCrossRefGoogle Scholar
  36. 36.
    Dijkhorst-Oei LT, Koomans HA: Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. Nephrol Dial Transplant 1998, 13:587–593.PubMedCrossRefGoogle Scholar
  37. 37.
    Harada S, Tokunaga S, Momohara M, et al.: Inhibition of nitric oxide formation in the nucleus tractus solitarius increases renal sympathetic nerve activity in rabbits. Circ Res 1993, 72:511–516.PubMedGoogle Scholar
  38. 38.
    Qiu C, Muchant D, Beierwaltes WH, et al.: Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function. Hypertension 1998, 31:21–26.PubMedGoogle Scholar
  39. 39.
    Halliwell B: What nitrates tyrosine?: Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 1997, 411:157–160.PubMedCrossRefGoogle Scholar
  40. 40.
    Ding Y, Gonick HC, Vaziri ND, et al.: Lead-induced hypertension: Increased hydroxyl radical production. Am J Hypertens 2001, 14:169–173.PubMedCrossRefGoogle Scholar
  41. 41.
    Vaziri ND, Oveisi F, Ding Y: Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998, 53:1748–1754.PubMedCrossRefGoogle Scholar
  42. 42.
    Vaziri ND, Ni Z, Oveisi F, et al.: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2001, 39:135–141.CrossRefGoogle Scholar
  43. 43.
    Schnackenberg CG, Welch WJ, Wilcox CS: Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 1998, 32:59–64.PubMedGoogle Scholar
  44. 44.
    Schnackenberg CG, Wilcox CS: Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 1999, 33:424–428.PubMedGoogle Scholar
  45. 45.
    Vaziri ND, Ni Z, Oveisi F, Tarnavsky-Hobbs DL: Effect of antioxidant therapy on blood pressure and nitric oxide synthase expression in hypertensive rats. Hypertension 2000, 36:975–964.Google Scholar
  46. 46.
    Lopez-Ongil S, Hernandez-Perera O, Navarro-Antolin J, et al.: Role of reactive oxygen species in the signaling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells. Br J Pharmacol 1998, 124:447–454.PubMedCrossRefGoogle Scholar
  47. 47.
    Roberts CK, Vaziri ND, Wang XQ, Barnard RJ: Enhanced NO inactivation and hypertension induced by a high-fat, refined carbohydrate diet. Hypertension 2000, 36:423–429.PubMedGoogle Scholar
  48. 48.
    Roberts CK, Vaziri ND, Liang K, Barnard RJ: Reversibility of chronic experimental syndrome X by diet modification. Hypertension 2000, 37:1323–1328.Google Scholar
  49. 49.
    Barton CH, Ni Z, Vaziri ND: Effect of server aortic banding above the renal arteries on nitric oxide synthase isotype expression. Kidney Int 2001, 59:654–661.PubMedCrossRefGoogle Scholar
  50. 50.
    Barton CH, Ni Z, Vaziri ND: Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 2001, 60:1083–1087.PubMedCrossRefGoogle Scholar
  51. 51.
    Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW: Oxidative stress in the Dahl hypertensive rat. Hypertension 1997, 30:1628–1633.PubMedGoogle Scholar
  52. 52.
    Roggensack AM, Zhang Y, Davidge ST: Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension 1999, 33:83–89.PubMedGoogle Scholar
  53. 53.
    Vaziri ND, Ding Y, Ni Z: Compensatory upregulation of NO synthase isoforms in lead-induced hypertension: reversal by an SOD-mimetic drug. J Pharmacol Exp Therap 2001, 298:679–685.Google Scholar
  54. 54.
    Vaziri ND, Wang XQ, Oveisi F, Rad B: Induction of oxidative stress by glutathione depletion causes hypertension in normal rats. Hypertension 2000, 36:142–146.PubMedGoogle Scholar
  55. 55.
    Vaziri ND, Wang XQ: cGMP-mediated negative feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 1999, 34:1237–1241.PubMedGoogle Scholar
  56. 56.
    Ding Y, Gonick HC, Vaziri ND: Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am J Hypertens 2000, 13:552–555.PubMedCrossRefGoogle Scholar
  57. 57.
    Ding Y, Vaziri ND, Gonick HC: Lead-induced hypertension. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside. Environ Res 1998, 76:107–113.PubMedCrossRefGoogle Scholar
  58. 58.
    Vaziri ND, Ding Y: Effect of lead on NO synthase expression in coronary endothelial cells: Role of superoxide. Hypertension 2001, 37:223–226.PubMedGoogle Scholar
  59. 59.
    Hsu PC, Guo YL: Antioxidant nutrients and lead toxicity. Toxicology 2002, 180:33–44. Comprehensive discussion of the role of antioxidants in modifying the effects of lead toxicity.PubMedCrossRefGoogle Scholar
  60. 60.
    Vaziri ND, Lin CY, Farmand F, Sindhu R: Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Kidney Int 2003, 63:186–194.PubMedCrossRefGoogle Scholar
  61. 61.
    Marques M, Millas I, Jimenez A, et al.: Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 2001, 12:2594–2600.PubMedGoogle Scholar
  62. 62.
    Courtois E, Marques M, Barrientos A, et al.: Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cycloxygenase-2. J Am Soc Nephrol 2003, 14:1464–1470. Description of the effect of lead-induced change in reactive oxygen species on soluble guanylate cyclase.PubMedCrossRefGoogle Scholar
  63. 63.
    Chang HR, Chen SS, Tsao DA, et al.: Reduced vascular betaadrenergic receptors and catecholamine response in rats with lead-induced hypertension. Arch Toxicol 1977, 71:778–781.CrossRefGoogle Scholar
  64. 64.
    Carmignani M, Volpe AR, Boscolo P, et al.: Catecholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci 2000, 68:401–415.PubMedCrossRefGoogle Scholar
  65. 65.
    Tsao DA, Yu HS, Cheng JT, et al.: The change of beta-adrenergic system in lead-induced hypertension. Toxicol Appl Pharmacol 2000, 164:124–133.CrossRefGoogle Scholar
  66. 66.
    Bertel O, Buhler FR, Ott J: Lead-induced hypertension: Blunted beta-adrenoceptor-mediated functions. Br Med J 1978, 1:551.PubMedGoogle Scholar
  67. 67.
    Keeton TK, Campbell WB: The pharmacologic alteration of renin release. Pharmacol Rev 1980, 32:81–227.PubMedGoogle Scholar
  68. 68.
    McAllister RG, Michelakis AM, Sandstead HH: Plasma renin activity in chronic plumbism. Arch Intern Med 1971, 127:919–923.PubMedCrossRefGoogle Scholar
  69. 69.
    Boscolo P, Carmignani M: Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect 1988, 78:101–106.PubMedCrossRefGoogle Scholar
  70. 70.
    Fleischer N, Mouw DR, Vander AJ: Chronic effects of lead on renin and renal sodium excretion. J Lab Clin Med 1980, 95:759–770.PubMedGoogle Scholar
  71. 71.
    Wilke L: Early and Late Effects of Neonatal Lead Exposure or In Vitro Renin Release [bstract]. Thorofare, NJ: American Society of Nephrology; 1987.Google Scholar
  72. 72.
    Nowack R, Wiecek A, Ritz E: Lead and hypertension. Contrib Neprhol 1992, 100:25–34.Google Scholar
  73. 73.
    Carmignani M, Boscolo P, Brandi G: Plasma renin activity to occupational lead exposure. Acta Med Rom 1988, 26:277–289.Google Scholar
  74. 74.
    Camignani M, Boscolo P, Poma A, Volpe AR: Kininergic system and arterial hypertension following chronic exposure to inorganic lead. Immunopharmacol 1999, 44:105–110.CrossRefGoogle Scholar
  75. 75.
    Terada Y, Tomita K, Nonoguchi H, et al.: Expression of endothelin-3 RNA along rat nephron segments using polymerase chain reaction. Kidney Int 1993, 44:1273–1280.PubMedGoogle Scholar
  76. 76.
    Cardenas A, Roels H, Bernard AM, et al.: Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. Br J Ind Med 1993, 50:28–36.PubMedGoogle Scholar
  77. 77.
    Hotter G, Fels LM, Closa D, et al.: Altered levels of urinary prostanoids in lead-exposed worker. Toxicol Lett 1995, 77:309–312.PubMedCrossRefGoogle Scholar
  78. 78.
    Gonick HC, Ding Y, Vaziri ND: Effect of low lead exposure on eicosanoid excretion in rats. Prost Lipid Med 1998, 55:77–82.Google Scholar
  79. 79.
    Piccinini F, Favalli L, Chiari MC: Experimental investigations on the contraction induced by lead in arterial smooth muscle. Toxicology 1977, 8:43–51.PubMedCrossRefGoogle Scholar
  80. 80.
    Kramer HJ, Gonick HC, Lu E: In vitro inhibition of Na-KATPase by trace metals: relation to renal and cardiovascular damage. Nephron 1986, 44:329–366.PubMedCrossRefGoogle Scholar
  81. 81.
    Snowdon CT, Sanderson BA: Lead pica produced in rats. Science 1974, 193:92–94.CrossRefGoogle Scholar
  82. 82.
    Mahaffey KR, Goyer R: Dose-response to lead ingestion in rats fed low dietary calcium. J Lab Clin Med 1973, 82:92–100.PubMedGoogle Scholar
  83. 83.
    Aungst BJ, Fung HL: The effects of dietary calcium on lead absorption, distribution and elimination kinetics in rats. J Toxicol Environ Health 1985, 16:147–159.PubMedCrossRefGoogle Scholar
  84. 84.
    Hwang KY, Schwartz BS, Lee BK, et al.: Associations of lead exposure and dose measures with erythrocyte protein kinase C activity in 212 current Korean lead workers. Toxicol Sci 2001, 62:280–288.PubMedCrossRefGoogle Scholar
  85. 85.
    Watts SW, Chai S, Webb RC: Lead acetate-induced contraction in rabbit mesenteric artery: interaction with calcium and protein kinase C. Toxicology 1995, 99:55–65.PubMedCrossRefGoogle Scholar
  86. 86.
    Chai SS, Webb RC: Effects of lead on vascular reactivity. Environ Health Perspect 1988, 78:85–89.PubMedCrossRefGoogle Scholar
  87. 87.
    Shelkovnikov SA, Gonick HC: Influence of lead on rat thoracic aorta contraction and relaxation. Am J Hypertension 2001, 14:873–878.CrossRefGoogle Scholar
  88. 88.
    Griffith LE, Guyatt GH, Cook RJ, et al.: The influence of dietary and non-dietary calcium supplementation on blood pressure: an updated meta-analysis of randomised controlled trials. Am J Hypertens 1999, 12:84–92.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Nosratola D. Vaziri
    • 1
  • Domenic A. Sica
    • 1
  1. 1.Division of Nephrology and HypertensionUniversity of California, Irvine, UCI Medical CenterOrangeUSA

Personalised recommendations